Our Pricing

Switch to Wegovy & Save: Complete Dose Conversion Guide

Considering how to switch to Wegovy dose conversion UK from your current weight loss treatment? At Cured Pharmacy, our UK-registered clinical team guides patients through safe dose transitions from Ozempic, Mounjaro, or Saxenda to Wegovy, with transparent pricing and personalised prescriber support. This comprehensive guide provides the exact conversion protocols used in clinical practice across the UK.

Understanding Wegovy Dose Conversion UK Protocols

Wegovy (semaglutide 2.4mg) follows a specific dose escalation schedule that differs from other GLP-1 receptor agonists, even when switching from medications containing the same active ingredient [1]. The MHRA-approved titration protocol starts at 0.25mg weekly and increases gradually over 16-20 weeks to reach the full therapeutic dose of 2.4mg, regardless of your previous treatment.

This gradual escalation isn't arbitrary — clinical trials demonstrated that slower dose increases significantly reduce gastrointestinal side effects whilst maintaining treatment adherence [1]. Even patients switching from Ozempic 1mg (which also contains semaglutide) must follow the complete Wegovy titration schedule, as the higher target dose requires physiological adaptation.

UK prescribers cannot skip titration steps or accelerate the schedule based on previous GLP-1 experience. The standardised approach ensures optimal tolerability whilst allowing your body to adjust to progressively higher semaglutide concentrations, which is critical for long-term treatment success.

Switching from Ozempic to Wegovy: Same Drug, Different Protocol

Many UK patients assume that switching from Ozempic to Wegovy is straightforward because both contain semaglutide. However, Ozempic's maximum licensed dose for type 2 diabetes is 1mg weekly, whilst Wegovy targets 2.4mg for weight management — a 140% increase that requires careful titration [2].

When transitioning from Ozempic 0.5mg or 1mg, your UK prescriber will typically advise stopping Ozempic and starting Wegovy at the initial 0.25mg dose within one week. This may seem like a step backwards, but the STEP clinical trial programme demonstrated that this approach optimises gastrointestinal tolerability as you progress toward the higher therapeutic dose [1][2].

The complete transition takes approximately 16-20 weeks to reach Wegovy 2.4mg. During this period, you may experience temporary weight plateau or minor regain, which is physiologically normal during dose escalation. Clinical data shows that patients who complete the full titration achieve significantly better long-term outcomes than those who attempt accelerated protocols.

Timing Your Switch from Ozempic

Semaglutide has a half-life of approximately 7 days, meaning therapeutic levels remain in your system for several weeks after your last injection [2]. UK prescribers typically recommend administering your first Wegovy 0.25mg dose 7 days after your final Ozempic injection to maintain consistent GLP-1 receptor activation whilst avoiding overlap.

If you've been on Ozempic for several months with good tolerability, this doesn't permit skipping Wegovy's initial doses. The MHRA-approved product licence requires all patients to follow the complete titration schedule, and UK prescribers must adhere to this licensed indication when issuing prescriptions.

Converting from Mounjaro to Wegovy: Different Mechanisms Require Full Titration

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, whilst Wegovy activates only GLP-1 receptors — fundamentally different pharmacological mechanisms despite both being weekly weight loss injections [3]. This means there's no direct dose equivalence, and all patients switching from Mounjaro must start Wegovy at 0.25mg regardless of their tirzepatide dose.

In clinical practice, patients transitioning from Mounjaro 10mg or 15mg to Wegovy often express concern about restarting at a much lower dose. However, the single-pathway GLP-1 activation of semaglutide 2.4mg produces substantial weight loss through different receptor dynamics than tirzepatide's dual action [3][4]. The STEP-1 trial demonstrated 14.9% average body weight reduction with Wegovy 2.4mg over 68 weeks, achieved through optimised GLP-1 receptor engagement [1].

UK prescribers recommend stopping Mounjaro and initiating Wegovy 0.25mg within 7 days. Some patients experience temporary weight stabilisation during the transition period, which typically resolves as you progress through Wegovy's dose escalation. Your clinical team at Cured Pharmacy can provide ongoing support throughout this adjustment phase, which is subject to prescriber approval based on your individual assessment.

Managing Expectations During Mounjaro to Wegovy Transition

Patients switching from higher Mounjaro doses should anticipate a 16-20 week titration period before reaching Wegovy's full 2.4mg therapeutic dose. During this time, weight loss velocity may temporarily slow compared to your Mounjaro results, particularly in the first 8-12 weeks.

Clinical experience shows that patients who maintain consistent lifestyle modifications during dose escalation achieve optimal outcomes once they reach Wegovy 2.4mg. The transition isn't a treatment failure — it's a necessary recalibration to a different pharmacological mechanism that has demonstrated robust efficacy in UK-licensed clinical trials [1][2].

Saxenda to Wegovy Conversion: From Daily to Weekly Injections

Saxenda (liraglutide 3mg) requires daily subcutaneous injections, whilst Wegovy offers once-weekly dosing — a significant convenience improvement that enhances long-term adherence [4]. Despite both being GLP-1 receptor agonists, the different molecular structures and dosing frequencies mean direct dose conversion isn't applicable.

When switching from Saxenda 3mg daily to Wegovy, UK prescribers follow the standard Wegovy titration protocol starting at 0.25mg weekly. You'll stop Saxenda and administer your first Wegovy injection within 24-48 hours, as liraglutide has a much shorter half-life (approximately 13 hours) compared to semaglutide's 7-day half-life [2][4].

Many patients report improved treatment satisfaction after switching from daily Saxenda to weekly Wegovy, beyond just injection frequency. Head-to-head trials haven't directly compared the two medications, but the STEP trials showed Wegovy 2.4mg produced greater average weight loss than historical liraglutide 3mg data, though individual results vary based on adherence and lifestyle factors [1][4].

Injection Burden Reduction

Transitioning from 365 annual Saxenda injections to 52 Wegovy injections represents an 86% reduction in injection frequency. Clinical studies consistently demonstrate that reduced dosing frequency improves medication adherence, particularly in long-term weight management programmes where treatment may continue for 12-24 months or longer [4].

The Wegovy pre-filled pen also offers simplified dosing — each pen contains a single fixed dose with no manual titration required, unlike Saxenda's adjustable dial that requires daily dose selection. This reduces user error and simplifies the injection routine for UK patients managing busy schedules.

Wegovy Dose Escalation Schedule: The Complete UK Protocol

The MHRA-approved Wegovy titration schedule follows this precise protocol: 0.25mg weekly for 4 weeks, 0.5mg weekly for 4 weeks, 1mg weekly for 4 weeks, 1.7mg weekly for 4 weeks, then 2.4mg weekly as the maintenance dose [1]. Each dose increase occurs at 4-week intervals to allow physiological adaptation and minimise gastrointestinal side effects.

UK prescribers may extend any dose level by an additional 4 weeks if you experience persistent nausea, vomiting, or diarrhoea. This flexibility is built into the licensed protocol and doesn't compromise efficacy — clinical trials showed that patients who required extended titration still achieved significant weight loss once they reached and maintained the 2.4mg dose [1].

If you miss more than 2 consecutive doses at any titration level, MHRA guidance recommends restarting at the previous lower dose to re-establish tolerability. Your UK prescriber will assess your specific situation and determine the appropriate restart protocol based on how long treatment was interrupted and which dose level you'd reached.

Cost Comparison: Why UK Patients Switch to Wegovy

At Cured Pharmacy, Wegovy starts from £79.00 per month with transparent upfront pricing shown before your free clinical consultation. This represents competitive UK pricing compared to typical market rates, with no hidden fees or subscription charges beyond the stated medication cost.

Many UK patients switch to Wegovy not only for clinical reasons but also for cost optimisation. Our pricing structure includes UK prescriber assessment, genuine MHRA-licensed medication, and discreet delivery — all covered in the stated price. The once-weekly injection schedule also means you're purchasing 4-5 doses per month rather than 28-30 daily injections, which can represent better value depending on your previous treatment.

All weight loss medications at Cured Pharmacy require online clinical assessment by a UK-registered prescriber, completed in under 3 minutes. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing to ensure you receive genuine UK-licensed Wegovy pens with full regulatory compliance. Patients switching from other treatments can discuss their previous medication history during the consultation, allowing prescribers to provide tailored switching guidance subject to clinical appropriateness.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). (2023). Electronic Medicines Compendium (eMC). https://www.medicines.org.uk/emc/product/13799
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or switching between weight loss treatments. Individual results may vary, and not all patients will be suitable for Wegovy based on their medical history and current health status.